PAPZIMEOS (zopapogene imadenovec-drba)

About Precigen

Precigen is a biopharmaceutical company specializing in innovative precision medicines for diseases with high unmet need, particularly in immuno-oncology, autoimmune disorders, and infectious diseases. The company has achieved a significant milestone with the FDA approval of PAPZIMEOS (zopapogene imadenovec-drba) for recurrent respiratory papillomatosis. Its strategic direction is built on two core, proprietary technology platforms: AdenoVerse for adenovector-based gene therapies and UltraCAR-T for rapidly manufactured, multi-gene CAR-T cell therapies, aiming to increase patient access and improve outcomes.

Therapeutic Areas

Other Recurrent Respiratory Papillomatosis (RRP) Drugs